Skip to main content
. Author manuscript; available in PMC: 2022 Aug 16.
Published in final edited form as: Cancer Res Commun. 2022 Jul 26;2022:10.1158/2767-9764.CRC-21-0143. doi: 10.1158/2767-9764.CRC-21-0143

Figure 4. Immune-related adverse events (irAEs) within the entire treatment cohort.

Figure 4.

A) Overall irAE rate as a function of race/ethnic group. B) ORR as a function of irAE for the ICI monotherapy cohort. CR: Complete response; PR: Partial response; SD: stable disease; PD: Progressive disease.